{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T06:02:32Z","timestamp":1771221752902,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1053\/j.semnuclmed.2025.11.017","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T20:22:05Z","timestamp":1765657325000},"page":"9-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment response assessment according to updated PROMISE criteria"],"prefix":"10.1053","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9939-282X","authenticated-orcid":false,"given":"Tugce","family":"Telli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4745-3501","authenticated-orcid":false,"given":"Caner","family":"Civan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-7259","authenticated-orcid":false,"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5106-3584","authenticated-orcid":false,"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0001","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer (1965)"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0002","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular Imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0003","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","article-title":"Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues","volume":"1","author":"Wright","year":"1995","journal-title":"Urolog Oncol: Semin Origin Investiga"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0005","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00259-021-05520-y","article-title":"Prospective intra-individual blinded comparison of [(18)F]PSMA-1007 and [(68) Ga]Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer","volume":"49","author":"Pattison","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0006","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41391-023-00755-2","article-title":"Comparison of (18)F-based PSMA radiotracers with [(68)Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer-a systematic review and meta-analysis","volume":"27","author":"Huang","year":"2024","journal-title":"Prostat Cancer Prostat Dis"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0007","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0008","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.eururo.2020.11.043","article-title":"Is prostate-specific membrane antigen positron emission tomography\/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA trial","volume":"79","author":"de Feria Cardet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0009","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of (68)Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study","volume":"59","author":"Roach","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0010","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","article-title":"Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant Prostate cancer","volume":"25","author":"Fendler","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0011","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0012","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0013","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0014","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0015","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1007\/s00259-025-07198-y","article-title":"Prognostic value of [(18)F]FDG- and PSMA-PET in patients evaluated for [(177)Lu]Lu-PSMA therapy of mCRPC","volume":"52","author":"Telli","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0016","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1007\/s00259-023-06281-6","article-title":"SUV(mean) on baseline [(18)F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [(177)Lu]Lu-PSMA I&T","volume":"50","author":"Hartrampf","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0017","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2967\/jnumed.122.265155","article-title":"Prognostic value of end-of-treatment PSMA PET\/CT in patients treated with (177)Lu-PSMA radioligand therapy: A retrospective, single-center analysis","volume":"64","author":"Murthy","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0018","first-page":"1651","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0019","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0020","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2967\/jnumed.123.267234","article-title":"RECIP 1.0 predicts progression-free survival after [177Lu]Lu-PSMA radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer","volume":"65","author":"Gafita","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0021","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-025-07592-6","article-title":"RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer","author":"Molin","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0022","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2967\/jnumed.118.223099","article-title":"Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade","volume":"60","author":"Emmett","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147431","article-title":"Enzalutamide enhances PSMA expression of PSMA-low prostate cancer","volume":"22","author":"Staniszewska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0024","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.2967\/jnumed.121.262120","article-title":"PSMA PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease","volume":"62","author":"Barbato","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13550-025-01229-3","article-title":"Pre- or post-chemotherapy: effect on PSMA uptake","volume":"15","author":"Yadav","year":"2025","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0026","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2967\/jnumed.121.263006","article-title":"(68)Ga-PSMA PET\/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy","volume":"63","author":"Shagera","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0027","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.125.269584","article-title":"[(68)Ga]Ga-PSMA-11 PET tumor volume predicts overall survival of patients with metastatic prostate cancer undergoing taxane-based chemotherapy","author":"Beintner-Skawran","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0028","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10585-020-10043-1","article-title":"The clinical efficacy of PSMA PET\/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial","volume":"37","author":"Joshi","year":"2020","journal-title":"Clin Exp Metast"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0029","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0030","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1055\/a-1697-8111","article-title":"Oligometastatic disease in biochemical recurrence of prostate cancer: prevalence on PSMA PET\/CT and consecutive metastasis-directed therapy - experience at a tertiary referral center","volume":"61","author":"M\u00fcller","year":"2022","journal-title":"Nuklearmedizin"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0031","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0032","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1186\/s12885-021-08026-w","article-title":"Phase 3 multicenter randomized trial of PSMA PET\/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol","volume":"21","author":"Calais","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0033","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0034","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","article-title":"METastasis reporting and Data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body Magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer","volume":"71","author":"Padhani","year":"2017","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0035","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.125.269971","article-title":"Prognostic value of AI-assisted lesion tracking on end-of-treatment PSMA PET in mCRPC patients treated with (177)Lu-PSMA: A retrospective, single-center study","author":"Murthy","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0036","doi-asserted-by":"crossref","first-page":"818","DOI":"10.21037\/atm-20-6446","article-title":"Decision-support for treatment with 177Lu-PSMA: machine learning predicts response with high accuracy based on PSMA-PET\/CT and clinical parameters","volume":"9","author":"Moazemi","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110869","article-title":"Kinetics of PSMA PET signal after radiotherapy in prostate cancer lesions: A single-center retrospective study","volume":"207","author":"Hotta","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0038","first-page":"14","article-title":"Upregulation of PSMA expression by enzalutamide in patients with advanced mCRPC","author":"Rosar","year":"2022","journal-title":"Cancer (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0039","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2967\/jnumed.119.233817","article-title":"Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: the PSMA PET progression criteria","volume":"61","author":"Fanti","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0040","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: A simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"JH","year":"2016","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2025.11.017_bib0041","doi-asserted-by":"crossref","first-page":"S970","DOI":"10.1016\/j.annonc.2024.08.1689","article-title":"1608P Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET\/CT for response evaluation: analysis from the PRINCE trial","volume":"35","author":"Hofman","year":"2024","journal-title":"Annal Oncol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T05:08:33Z","timestamp":1771218513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825001709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0001299825001709"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.017","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment response assessment according to updated PROMISE criteria","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}